Holen Sie sich die Stockscreener-App
0.00
2.94%
-0.102
Neximmune Inc Aktie (NEXI) Neueste Nachrichten
NexImmune, Inc. Revenue Breakdown – OTC:NEXI - TradingView
Neximmune Inc (NEXI) Peer Comparison – Compare with Others - valueresearchonline.com
NexImmune, Inc. Revenue Breakdown – LS:A3EUTV - TradingView
NexImmune stock trades on delisting news after business combination progress - Ad-hoc-news.de
Price to earnings forward of NexImmune, Inc. – OTC:NEXI - TradingView
Price to book forward of NexImmune, Inc. – OTC:NEXI - TradingView
Price to sales forward of NexImmune, Inc. – OTC:NEXI - TradingView
Enterprise value to revenue forward of NexImmune, Inc. – OTC:NEXI - TradingView
Enterprise value to EBIT forward of NexImmune, Inc. – OTC:NEXI - TradingView
NexImmune, Inc. Actuals & Estimates (LS:A3EUTV) - TradingView
Nextcom’s 2019 Omnibus Incentive Plan Amendment Approved: Key Shareholder Voting Results and Executive Compensation Insights – Minichart - Minichart
NexImmune StockSaturday deep dive into the immunotherapy micro-cap - AD HOC NEWS
Number of shareholders of NexImmune, Inc. – OTC:NEXI - TradingView
NexImmune Inc stock (US65343B1044): small-cap biotech pivots as it explores strategic options - AD HOC NEWS
NexImmune Inc stock (US65343B1044): what’s next after the reverse merger with MEI Pharma - AD HOC NEWS
NexImmune Inc stock (US65343B1044): Nasdaq delisting shifts focus to restructuring - AD HOC NEWS
Halia Therapeutics to Present Final Phase 2 Ofirnoflast Data in Lower-Risk MDS at EHA2026 and Announces Appointment of Han Myint, MD, FACP, as Chief Medical Officer - Bolsamania
NexImmune Inc stock (US65343B1044): Is its T-cell therapy platform strong enough to unlock biotech u - AD HOC NEWS
NexImmune Inc stock (US65343B1044): Is its T cell platform strong enough to unlock immunotherapy ups - AD HOC NEWS
NexImmune (NEXI) was downgraded to a Hold Rating at Citi - The Globe and Mail
ITRMF Stock Price and Chart — OTC:ITRMF - TradingView
Stock List: Research Stocks from Around the World - gurufocus.com
NexImmune Inc stock faces renewed scrutiny amid clinical trial updates and biotech sector volatility - AD HOC NEWS
NexImmune Inc stock faces renewed scrutiny amid biotech sector volatility and pipeline updates - AD HOC NEWS
NexImmune Inc Stock (ISIN: US65343B1044): Immunotherapy Play Eyes Clinic Expansion Amid Biotech Vola - AD HOC NEWS
NexImmune Inc Stock (ISIN: US65343B1044) Faces Volatility Amid Biotech Sector Pressures - AD HOC NEWS
Contrasting ASLAN Pharmaceuticals (NASDAQ:ASLN) & NexImmune (OTCMKTS:NEXI) - Defense World
NexImmune Inc Is Exploding Online – But Is NEXI Stock a Hidden Gem or a Total Trap? - AD HOC NEWS
The Truth About NexImmune Inc: Why Everyone Is Suddenly Watching This Micro-Cap Wildcard - AD HOC NEWS
NexImmune’s Vanishing Act: What Happens When a Ticker Survives but the Company Does Not? - AD HOC NEWS
NexImmune (NEXI) Short Interest & Short Float | Updated May 2026 - MarketBeat
NexImmune (NEXI) Stock Price, News & Analysis - MarketBeat
Eloxx Pharmaceut (ELOX) Stock Price, News & Analysis - Stock Titan
NEXI Stock Price, News & Analysis - Stock Titan
SYRS Stock Price and Chart — OTC:SYRS - TradingView
Vanotech Appoints Matthew Schiller to Lead Business Development - citybiz
TRVN Stock Price and Chart — OTC:TRVN - TradingView
Neximmune Inc (NEXI) Stock Price and News - The Globe and Mail
Immunomodulators Market Size to Worth Around US$ 1,237.66 Bn by 2033 - BioSpace
NexImmune moves forward with wind-down process - bizjournals.com
NEXI S-8 POS & SEC FilingsYahoo Finance - Yahoo! Finance Canada
NexImmune shareholders approve company dissolution - Investing.com
NexImmune adjourns special meeting to explore options By Investing.com - Investing.com UK
NEXI Stock Price and Chart — OTC:NEXI - TradingView
NEXI Stock Alert: NexImmune Delists From Nasdaq - InvestorPlace
NexImmune Faces Nasdaq Delisting, Adjourns Shareholder Meeting - Investing.com
LSDIF Stock Price and Chart — OTC:LSDIF - TradingView
VAXX Stock Price and Chart — OTC:VAXX - TradingView
PBLA Stock Price and Chart — OTC:PBLA - TradingView
Zhengbin Yao Net WorthInsider Trades and Bio as of Apr 21, 2026 - Benzinga
NexImmune Announces Closing of $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Stock Titan
NEXI 8-K & SEC FilingsYahoo Finance - Yahoo! Finance Canada
What's going on in today's session - ChartMill
Tuesday's session: top gainers and losers - ChartMill
Pre-market Movers: JFBR, AREN, ATIF, ABVC, NEXI… - RTTNews
Top movers in Wednesday's pre-market session - ChartMill
NexImmune's future in limbo as Gaithersburg biotech extends liquidation vote - The Business Journals
EVLO Stock Price and Chart — OTC:EVLO - TradingView
Gaithersburg’s NexImmune prepares to shut down, lay off ‘substantially all’ employees - The Business Journals
Neximmune Inc Share Price USD0.0001 - Hargreaves Lansdown
Rockville cancer therapy firm Sensei Biotherapeutics faces delisting threat from Nasdaq - bizjournals.com
NexImmune (NASDAQ: NEXI) to jump 2,500% todaya purely technical move - Dhaka Tribune
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. - ChartMill
Paul D'angio Net Worth (2026) - GuruFocus
NexImmune, Inc. (NEXI) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Robert Douglas Knight Net Worth (2026) - GuruFocus
NexImmune, Inc. (NEXI) Stock Live Price, Chart & News - CoinCodex
Monday's after hours session: top gainers and losers - ChartMill
Unusual volume stocks in Friday's session - ChartMill
These stocks are gapping in today's session - ChartMill
Timothy Bertram Net Worth (2026) - GuruFocus
Neximmune : Failure to Satisfy Listing RuleForm 8-K - marketscreener.com
AIM™ platform: A new immunotherapy approach for viral diseases - Frontiers
Mathias Oelke Net Worth (2026) - GuruFocus
0.88%
Kapitalisierung:
|
Volumen (24h):